Curocell Inc.
Research Curocell Inc. (372320.KQ) on Bullrun: market cap KRW 357.81B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker372320.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 357.81B
- Financial periodQ2 2026
- Net income-KRW 17.65B
- Free cash flow-KRW 8.05B
Valuation Snapshot
latest market cap is KRW 357.81B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 357.81B | n/a | n/a | n/a |
Dividend history
About Curocell Inc.
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Curocell Inc.'s market cap?
Curocell Inc.'s market capitalization is KRW 357.81B.
What does Curocell Inc. do?
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals. It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors. The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T. Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.